Adenocarcinoma: all 1,996 studies

Page 9 of 20. Open to participants first (369), then studies with results posted, then the rest; newest registration first within each.

• PARA (Pancreatic Adenocarcinoma Etiology: Role of Asbestos) Study of Risk Factors for Exocrine Pancreatic Neoplasms.Active, not recruitingNCT06815172
• Development of a Novel Signature Integrating Clinical, Imaging And Epigenetic Information to Tailor Pelvic Nodal Treatment in Prostate CancerCompletedNCT06807398
• Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast CarcinomasActive, not recruitingNCT06805084
• Study on the Applicability of CCR Criteria in Rectal CancerCompletedNCT06794099
• POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)Active, not recruitingNCT06790238
• RT for Cervical Adenocarcinoma/adenosquamous CarcinomaActive, not recruitingNCT06741046
• Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJActive, not recruitingNCT06739161Phase 2
• Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric AdenocarcinomaSuspendedNCT06728657Phase 2
• Study on Single-cell Regulons Atlas of Pancreatic Ductal AdenocarcinomaCompletedNCT06720454
• Molecular Analysis of Gastric and OEsophageal Cancers STudyWithdrawnNCT06702384
• Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric CancerActive, not recruitingNCT06693128Phase 2
• A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabActive, not recruitingNCT06681298Phase 2
• CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric CancerActive, not recruitingNCT06667050Phase 2
• Understanding the Benefits of Dietary Fibre Supplementation in Patients With Prostate CancerCompletedNCT06661044
• Deep Learning Model to Predict the Recurrence of Stage IA Invasive Lung Adenocarcinoma After Sub-lobar ResectionCompletedNCT06659601
• Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging EvaluationsTerminatedNCT06655064
• MRI and CT in Gastroesophageal Junction or Upper Gastric AdenocarcinomaActive, not recruitingNCT06640153
• Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Advanced and Metastatic High-Grade Adenocarcinoma of Ovarian, Tubal or Peritoneal Origin (TUPRO-Gyn)CompletedNCT06599749
• Certepetide Phase 1b/2a Continuous Infusion Trial in mPDACWithdrawnNCT06592664Phase 1/2
• Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal CancerWithdrawnNCT06575725Phase 2
• A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological FeaturesActive, not recruitingNCT06564844Phase 3
• The Effect of Albumin Value, HALP Score, and LCR Value on Predicting Survival and Recurrence in Patients With Pancreatic AdenocarcinomaCompletedNCT06553040
• Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in FranceActive, not recruitingNCT06504615
• Surveillance Endoscopy After Proximal Gastriectomy With Double Tract Reconstruction.CompletedNCT06477562
• DNA Methylation Biomarkers to Predict Survival After Surgery for Lung AdenocarcinomaCompletedNCT06477211
• Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT06440811
• Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal AdenocarcinomaWithdrawnNCT06398587Phase 2
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal AdenocarcinomaCompletedNCT06381583
• Risk Factors of Postoperative Complications and Survival Rate in Pancreatic Ductal Adenocarcinoma PatientsCompletedNCT06378853
• The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT06378580
• EchoTip AcuCore Post-Market Clinical StudyCompletedNCT06358001
• Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal AdenocarcinomaCompletedNCT06344299
• EUS Role in Non-metastatic Pancreatic Adenocarcinoma Lymph Nodes StagingTerminatedNCT06341725
• Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201WithdrawnNCT06341647Phase 1
• A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric AdenocarcinomaCompletedNCT06337266
• A Deep Learning Radiomics Model for Predicting Occult Peritoneal Metastases of Pancreatic AdenocarcinomaCompletedNCT06336694
• Digital Confocal Microscopy for Real-time Diagnosis of Pancreatic Solid LesionCompletedNCT06315439
• Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate CancerCompletedNCT06312670Phase 2
• Differentiating Tumor-stroma Ratio in Pancreatic Ductal AdenocarcinomaActive, not recruitingNCT06302881
• A Study Using 18F-FAPI PET to Evaluate Treatment Response in Pancreatic AdenocarcinomaCompletedNCT06277206
• Poorly Differentiated Adenocarcinoma of the Jejunum in a Patient With Peutz-Jeghers Syndrome: A Case ReportCompletedNCT06242457
• First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GCCompletedNCT06238752Phase 2
• A Study of IMM-6-415 in RAS/RAF Mutant Solid TumorsCompletedNCT06208124Phase 1/2
• FL118 for Treating Patients With Advanced Pancreatic Ductal AdenocarcinomaWithdrawnNCT06206876Phase 1
• Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal AdenocarcinomaCompletedNCT06199752Phase 4
• caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.Active, not recruitingNCT06171854Phase 2
• Microbiota and Metabolites Alterations in Pancreatic Head and Body/Tail Cancer PatientsCompletedNCT06147154
• Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung CancerCompletedNCT06145750Not applicable
• Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based StudyCompletedNCT06087887
• Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted TherapyCompletedNCT06083974
• HER-2 Expression in Pancreatic Duct AdenocarcinomaCompletedNCT06055647
• Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRCCompletedNCT06031376
• Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based TherapyCompletedNCT06006728
• Combined Segmentectomy Versus Lobectomy for Stage IA Lung Adenocarcinoma With Ground-glass Component of Prospective, Randomized, Controlled Clinical StudyActive, not recruitingNCT05983835Not applicable
• Tumor MicroenvironmentActive, not recruitingNCT05982574
• A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACActive, not recruitingNCT05968326Phase 2
• Hürthle Cell Carcinoma and Follicular Thyroid CarcinomaCompletedNCT05968196
• Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas.CompletedNCT05959213
• Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II TrialStatus unknownNCT05942573Phase 2
• Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)TerminatedNCT05935748Phase 2
• Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the PancreasWithdrawnNCT05926206Phase 1/2
• Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerActive, not recruitingNCT05922930Phase 1/2
• Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma.Status unknownNCT05919381Phase 3
• Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal JunctionStatus unknownNCT05918419Phase 2
• Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)Active, not recruitingNCT05915351Phase 2
• HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in RussiaCompletedNCT05892926
• 18F-FAPI PET Imaging in Pancreatic AdenocarcinomaCompletedNCT05884463Not applicable
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersActive, not recruitingNCT05873686Phase 1
• The Safety and Feasibility of MONOFIX on Fascial Closure of Mid-line Wound After Minimally Invasive Colorectal Cancer SurgeryCompletedNCT05872334Not applicable
• A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal GastrectomyStatus unknownNCT05829213Not applicable
• Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric AdenocarcinomaStatus unknownNCT05816863
• A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid TumorsActive, not recruitingNCT05812027
• Characterisation of the Intratumoral Microbiome in Gastric Adenocarcinoma: to a Personalised MedicineStatus unknownNCT05800236Not applicable
• Study of RO7515629 in Participants With HLA-G Positive Solid TumorsTerminatedNCT05769959Phase 1
• Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D MutationTerminatedNCT05737706Phase 1
• Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung AdenocarcinomaStatus unknownNCT05736991
• A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric CancerStatus unknownNCT05705635Phase 2
• Public's Intended Uptake and Views on Organization of Esophageal Cancer ScreeningStatus unknownNCT05690958
• Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for Gastric Adenocarcinoma.TerminatedNCT05687617Phase 2
• Preoperative Evaluation of Lymph Nodes of CholangiocarcinomaCompletedNCT05678218
• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative RadiomicsStatus unknownNCT05669287Not applicable
• Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the ProstateWithdrawnNCT05647447Early Phase 1
• Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal CancerStatus unknownNCT05635149
• Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaActive, not recruitingNCT05625737Phase 2
• Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2
• Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Locally Advanced/Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction Based on Different GenotypesStatus unknownNCT05608785Phase 1/2
• Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the ProstateTerminatedNCT05607342Early Phase 1
• Clinical, Histological and Prognostic Forms of Adenocarcinoma of the AnusStatus unknownNCT05605873
• Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour LipidomeStatus unknownNCT05600608Not applicable
• Stereotactic Prostate Radiotherapy With Dose Escalation Focused on the "Dominant Intra-prostatic Lesion" (DIPL) Delineated by Multi-parametric MRI and 68Ga-PSMA PET (Prostate-SIB-PSMA)Status unknownNCT05599737Not applicable
• A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05585320Phase 1/2
• Prognostic Value of Myosteatosis and Creatinine-to-cystatin C Ratio in Patients With Pancreatic Ductal AdenocarcinomaStatus unknownNCT05584852
• A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ TrastuzumabStatus unknownNCT05583383Not applicable
• Poorly Differentiated Adenocarcinoma With Signet Ring Cells of the Gallbladder Producing a High Level of Alpha-fetoprotein: a Case ReportCompletedNCT05559229
• Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the PancreasStatus unknownNCT05557851Phase 1
• A New Prognostic Score Model for Pancreatic Ductal AdenocarcinomaCompletedNCT05547074
• Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal AdenocarcinomaCompletedNCT05540145
• A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the OvaryTerminatedNCT05538624Phase 1/2

← Adenocarcinoma overview